Mechanisms of main components in Curcuma longa L. on hepatic fibrosis based on network pharmacology and molecular docking: A review.

BACKGROUND

Hepatic fibrosis is a great concern in public health. While effective drugs for its treatment are lacking, Curcuma longa L. (CL) has been reported as a promising therapeutic. We aimed to uncover the core components and mechanisms of CL against hepatic fibrosis via a network pharmacology approach.

METHODS

The main components of CL were obtained and screened. While targets of components and disease were respectively collected using SwissTargetPrediction and online databases, common targets were assessed. A protein-protein interaction (PPI) network was constructed, and core targets were identified. GO and KEGG pathway enrichment analyses were performed, and molecular docking was conducted to validate the binding of core components in CL on predicted core targets.

RESULTS

Nine main components from CL based on high-performance liquid chromatography (HPLC) and 63 anti-fibrosis targets were identified, and a PPI network and a component target-disease target network were constructed. Apigenin, quercetin, demethoxycurcumin, and curcumin are likely to become key phenolic-based components and curcuminoids for the treatment of hepatic fibrosis, respectively. KEGG pathway enrichment analysis revealed that the HIF-1 signaling pathway (hsa04066) was most significantly enriched. Considering core targets of the PPI network and a network of the common targets and pathways enriched, AKT1, MAPK1, EGFR, MTOR, and SRC may be the core potential targets of CL against hepatic fibrosis. Molecular docking was carried out to verify the binding of above core components to core targets.

CONCLUSIONS

The therapeutic effect of CL on hepatic fibrosis may be attributed to multi-components, multi-targets, and multi-pathways.